Latest From CrystalGenomics Inc.
South Korea continues to ease stock market listing rules to help bioventures and other innovative companies sustain growth and focus on their core R&D activities.
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.
Application of artificial intelligence to new drug development in South Korea, which has been lagging in this area, is poised to accelerate as the country moves to support and encourage the technology.
Amid increasing exports of new drug Acelex and multiple out-licensing agreements for its investigative oncology drugs, the South Korean biotech is raising sizable new funds via stocks and bonds this year to seek new longer term growth engines by bringing in new drug assets, or seeking M&As and alliances, and speeding up progress of its R&D pipeline in global markets.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- CrystalGenomics Inc.
- Senior Management
Joong Myung Cho, Pres. & CEO
Cheong Ahn Sang, VP, CFO
Rho Seonggu, PhD, VP, CTO
- Contact Info
Phone: (82) 31-628-2700
5F, Tower A, Korea Bio Park, 694-1, Samp
Bundang-gu, Seongnam-si, 463-400
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.